#Ribo_Life_Science
LightNews LightNews
newsen.bsky.social
Ribo Announces Phase 2 Clinical Trial Application for siRNA Therapeutics Targeting Thromboembolic Diseases#China#Suzhou#siRNA_therapy#coronary_artery_disease#Ribo_Life_Science
Ribo Announces Phase 2 Clinical Trial Application for siRNA Therapeutics Targeting Thromboembolic Diseases
Suzhou Ribo Life Science and Ribocure Pharmaceuticals announced the submission of a Phase 2 clinical trial application to the EMA for siRNA-based therapy aimed at coronary artery disease, marking a significant advancement in thromboembolic treatment.
third-news.com
May 28, 2026 at 5:05 PM
newsen.bsky.social
Ribo Expands Its Reach Beyond the Liver with Innovative RiboPepSTAR™ Technology#China#Suzhou#Ribo_Life_Science#siRNA_Technology#RiboPepSTAR
Ribo Expands Its Reach Beyond the Liver with Innovative RiboPepSTAR™ Technology
Suzhou Ribo Life Science unveils RiboPepSTAR™, a groundbreaking technology for targeted siRNA delivery to organs beyond the liver, opening new therapeutic possibilities.
third-news.com
March 20, 2026 at 11:35 AM
newsen.bsky.social
Ribo and Madrigal Reach Major Milestone in siRNA Therapy for MASH Development#China#Suzhou#siRNA_therapy#Ribo_Life_Science#Madrigal_Pharmaceuticals
Ribo and Madrigal Reach Major Milestone in siRNA Therapy for MASH Development
Suzhou Ribo Life Science and Madrigal Pharmaceuticals celebrate a significant milestone in the development of novel siRNA therapies for MASH, a liver disease.
third-news.com
July 2, 2026 at 2:59 PM
newsen.bsky.social
Ribo Advances siRNA Therapeutics with Phase 2 Clinical Trial Submission to EMA#China#Suzhou#coronary_artery_disease#Ribo_Life_Science#siRNA_therapeutics
Ribo Advances siRNA Therapeutics with Phase 2 Clinical Trial Submission to EMA
Suzhou Ribo Life Science has officially submitted a Phase 2 Clinical Trial for RBD1119, targeting coronary artery disease with innovative siRNA therapies.
third-news.com
May 28, 2026 at 2:55 AM
newsen.bsky.social
Ribo Life Science Revolutionizes siRNA Delivery with RiboPepSTAR™ to Target Multiple Organs#China#Suzhou#Ribo_Life_Science#RNA_Leaders#RiboPepSTAR
Ribo Life Science Revolutionizes siRNA Delivery with RiboPepSTAR™ to Target Multiple Organs
Suzhou Ribo Life Science is pioneering targeted delivery of small interfering RNA to organs beyond the liver, showcasing promising preclinical results with RiboPepSTAR™.
third-news.com
March 20, 2026 at 11:34 AM
newsen.bsky.social
Positive Phase 2a Findings for Vortosiran: A Breakthrough in siRNA-mediated FXI Inhibition#China#Shanghai#Ribo_Life_Science#Vortosiran#Fakelixir
Positive Phase 2a Findings for Vortosiran: A Breakthrough in siRNA-mediated FXI Inhibition
Suzhou Ribo Life Science announces promising Phase 2a data for Vortosiran, a significant siRNA therapy targeting FXI in coronary artery disease patients.
third-news.com
July 23, 2026 at 12:12 AM
newsen.bsky.social
Groundbreaking Phase 2a Trial Results for Vortosiran Show Potential in Antithrombotic Treatments#China#Shanghai#Clinical_Trials#Ribo_Life_Science#Vortosiran
Groundbreaking Phase 2a Trial Results for Vortosiran Show Potential in Antithrombotic Treatments
Suzhou Ribo Life Science announces encouraging Phase 2a trial results for Vortosiran, demonstrating significant inhibition of factor XI with potential antithrombotic benefits for coronary artery disease patients.
third-news.com
July 23, 2026 at 11:35 AM
newsen.bsky.social
Suzhou Ribo Life Science Advances Clinical Trials for RNAip Therapy in Treating Thromboembolic Diseases#China#Suzhou#Ribo_Life_Science#RBD1119#RNAip_Therapy
Suzhou Ribo Life Science Advances Clinical Trials for RNAip Therapy in Treating Thromboembolic Diseases
Suzhou Ribo Life Science has announced the submission of a phase 2 clinical trial application to the EMA for RBD1119, targeting coronary artery disease.
third-news.com
May 28, 2026 at 5:14 PM
newsen.bsky.social
Insilico Medicine and Ribo Forge Strategic Alliance for Advancing RNA Therapeutics Through AI Innovations#China#Shanghai#Insilico_Medicine#AI_Drug_Development#Ribo_Life_Science
Insilico Medicine and Ribo Forge Strategic Alliance for Advancing RNA Therapeutics Through AI Innovations
Insilico Medicine and Ribo Life Science have embarked on a collaboration to leverage AI in the development of RNA interference therapeutics, enhancing research capabilities.
third-news.com
May 13, 2026 at 9:51 AM
newsen.bsky.social
Ribo's Vortosiran Phase 2a Trial Yields Promising Results for Coronary Artery Disease Treatment#China#Shanghai#coronary_artery_disease#Ribo_Life_Science#Vortosiran
Ribo's Vortosiran Phase 2a Trial Yields Promising Results for Coronary Artery Disease Treatment
Suzhou Ribo Life Science announces positive outcomes from the Phase 2a trial of Vortosiran, the first siRNA therapy targeting FXI in chronic coronary artery disease patients.
third-news.com
July 22, 2026 at 2:20 PM
newsen.bsky.social
Breakthrough Phase 2a Results for Vortosiran Highlight siRNA’s Potential in Treating Coronary Artery Disease#China#Shanghai#siRNA_therapy#Ribo_Life_Science#Vortosiran
Breakthrough Phase 2a Results for Vortosiran Highlight siRNA’s Potential in Treating Coronary Artery Disease
Suzhou Ribo Life Science unveiled promising Phase 2a trial results for Vortosiran, a revolutionary siRNA therapy showing significant FXI inhibition in coronary artery disease patients.
third-news.com
July 22, 2026 at 12:29 PM
newsen.bsky.social
Ribo Reveals Groundbreaking Phase 2a Trial Results for Vortosiran: First Clinical Data on siRNA FXI Inhibition in CAD Patients#China#Shanghai#Ribo_Life_Science#Vortosiran#FXI_Inhibition
Ribo Reveals Groundbreaking Phase 2a Trial Results for Vortosiran: First Clinical Data on siRNA FXI Inhibition in CAD Patients
Ribo Life Science announces promising Phase 2a data on Vortosiran, showcasing successful FXI inhibition in coronary artery disease patients, paving the way for innovative therapies.
third-news.com
July 22, 2026 at 12:48 PM
newsen.bsky.social
Ribo and Madrigal Achieve Milestone in siRNA Therapy Development for MASH#China#Suzhou#MASH#Ribo_Life_Science#Madrigal_Pharmaceuticals
Ribo and Madrigal Achieve Milestone in siRNA Therapy Development for MASH
Suzhou Ribo Life Science and Madrigal Pharmaceuticals have successfully completed a significant milestone in developing siRNA therapies for metabolic dysfunction-associated steatohepatitis (MASH).
third-news.com
July 2, 2026 at 4:54 AM
newsen.bsky.social
Ribo Life Science and Madrigal Pharmaceuticals Hit Key Milestone in siRNA Therapy Development for MASH#China#Suzhou#MASH#siRNA#Ribo_Life_Science
Ribo Life Science and Madrigal Pharmaceuticals Hit Key Milestone in siRNA Therapy Development for MASH
Suzhou Ribo Life Science and Madrigal Pharmaceuticals celebrate a significant milestone in advancing siRNA therapies for MASH, with plans for clinical study initiation.
third-news.com
July 2, 2026 at 1:47 AM
newsen.bsky.social
Suzhou Ribo Life Science and Madrigal Pharmaceuticals Milestone in siRNA Therapy Development#China#Suzhou#Ribo_Life_Science#siRNA_therapies#Madrigal_Pharmaceuticals
Suzhou Ribo Life Science and Madrigal Pharmaceuticals Milestone in siRNA Therapy Development
Suzhou Ribo Life Science and Madrigal Pharmaceuticals have successfully reached a key milestone in their siRNA partnership, focusing on innovative treatments for liver diseases.
third-news.com
July 2, 2026 at 1:26 AM
newsen.bsky.social
Ribo and Insilico Medicine: A Strategic Alliance to Transform Drug Development Using AI#China#Suzhou#Insilico_Medicine#Ribo_Life_Science#siRNA_drug
Ribo and Insilico Medicine: A Strategic Alliance to Transform Drug Development Using AI
Suzhou Ribo Life Science has partnered with Insilico Medicine to leverage AI for advanced siRNA drug development. This collaboration aims to tackle unmet clinical needs through innovative solutions.
third-news.com
May 13, 2026 at 1:22 PM
newsen.bsky.social
Ribo and Insilico Medicine Form Strategic Alliance to Innovate siRNA Drug Development with AI#Insilico_Medicine#Ribo_Life_Science#siRNA_drug_development
Ribo and Insilico Medicine Form Strategic Alliance to Innovate siRNA Drug Development with AI
Ribo Life Science partners with Insilico Medicine to enhance siRNA drug development leveraging artificial intelligence. This collaboration aims to accelerate innovative solutions for unmet clinical needs.
third-news.com
May 13, 2026 at 9:55 AM
newsen.bsky.social
Ribo and Boehringer Ingelheim Achieve Milestone in siRNA Program for Metabolic Dysfunction-Associated Steatohepatitis#China#Suzhou#Boehringer_Ingelheim#MASH#Ribo_Life_Science
Ribo and Boehringer Ingelheim Achieve Milestone in siRNA Program for Metabolic Dysfunction-Associated Steatohepatitis
Suzhou Ribo Life Science and Ribocure Pharmaceuticals have marked a significant achievement in their siRNA program aimed at treating metabolic dysfunction-associated liver disease, MASH.
third-news.com
May 7, 2026 at 5:44 AM
newsen.bsky.social
Suzhou Ribo and Boehringer Ingelheim Achieve New Milestone in siRNA Program for Liver Disease#China#Suzhou#Boehringer_Ingelheim#Ribo_Life_Science#siRNA_Program
Suzhou Ribo and Boehringer Ingelheim Achieve New Milestone in siRNA Program for Liver Disease
Suzhou Ribo Life Science and Boehringer Ingelheim have reached a significant milestone in their collaboration focusing on new therapies for metabolic liver diseases.
third-news.com
May 6, 2026 at 5:12 PM
newsen.bsky.social
Ribo Life Science Unveils RiboPepSTAR™ for Targeted siRNA Delivery Across Multiple Organs#China#Suzhou#Ribo_Life_Science#siRNA_Technology#RiboPepSTAR™
Ribo Life Science Unveils RiboPepSTAR™ for Targeted siRNA Delivery Across Multiple Organs
Ribo Life Science introduces RiboPepSTAR™, a revolutionary technology enabling targeted siRNA delivery to various organs, enhancing RNA therapies for renal and metabolic diseases.
third-news.com
March 20, 2026 at 7:21 AM
newsen.bsky.social
Ribo Life Science to Showcase Extrahepatic Drug Delivery Innovations at RNA Leaders Europe Conference#China#Suzhou#Ribo_Life_Science#RNA_Leaders#RiboPepSTAR
Ribo Life Science to Showcase Extrahepatic Drug Delivery Innovations at RNA Leaders Europe Conference
Ribo Life Science will present new data on extrahepatic drug delivery using its RiboPepSTAR platform at the RNA Leaders Europe Conference in Vienna, showcasing future therapeutic possibilities.
third-news.com
March 18, 2026 at 2:46 AM
newsen.bsky.social
Ribo Life Science to Present Innovative Ex-Hepatic Delivery Research at RNA Leaders Europe Conference in Vienna#China#Suzhou#Ribo_Life_Science#RNA_Leaders#RiboPepSTAR
Ribo Life Science to Present Innovative Ex-Hepatic Delivery Research at RNA Leaders Europe Conference in Vienna
Suzhou Ribo Life Science Co., Ltd. will showcase their groundbreaking ex-hepatic delivery platform at the RNA Leaders Europe Conference, highlighting innovative therapies.
third-news.com
March 18, 2026 at 2:43 AM
newsen.bsky.social
Ribo to Showcase Innovative Ex-Hepatic Delivery at RNA Leaders Europe Conference#China#Suzhou#Ribo_Life_Science#RNA_Leaders#RiboGalSTAR
Ribo to Showcase Innovative Ex-Hepatic Delivery at RNA Leaders Europe Conference
Suzhou Ribo Life Science Co., Ltd. is set to present its groundbreaking ex-hepatic delivery platform at RNA Leaders Europe, highlighting its advancements in RNA therapy.
third-news.com
March 17, 2026 at 3:07 AM
newsen.bsky.social
Ribo Presents Innovative Ex-Hepatic Delivery Data at RNA Leaders Europe Conference#China#Suzhou#RNA_Therapeutics#Ribo_Life_Science#siRNA_Technology
Ribo Presents Innovative Ex-Hepatic Delivery Data at RNA Leaders Europe Conference
Suzhou Ribo Life Science is set to share groundbreaking data on ex-hepatic delivery technologies at the RNA Leaders Europe Conference, aimed at expanding siRNA applications.
third-news.com
March 17, 2026 at 3:07 AM
newsen.bsky.social
Ribo and Ribocure Forge Exclusive Global Licensing Deal with Madrigal for Novel pARNi Therapies#China#Suzhou#Ribo_Life_Science#Ribocure_Pharmaceuticals#Madrigal_Pharmaceuticals
Ribo and Ribocure Forge Exclusive Global Licensing Deal with Madrigal for Novel pARNi Therapies
Suzhou Ribo Life Science and Ribocure have secured an exclusive global license agreement with Madrigal for innovative pARNi therapies targeting metabolic dysfunction-associated steatohepatitis (MASH).
third-news.com
February 12, 2026 at 10:58 AM